Powered by Clearbit

Merck & Co Inc (NYS: MRK)

General Company Information

Principal Office Website
2000 Galloping Hill Road Kenilworth www.merck.com

Phone Primary NAICS

908 740-4000 325412 : Pharmaceutical Preparation Manufacturing

Fax Closing Stock Price

908 735-1500 88.36 (as of 02/04/2020)

Auditor Incorporated
PricewaterhouseCoopers LLP June 1927 , NJ, United States

Number of Employees Mergent Dividend Achiever

69,000 (Approximate Full-Time as of No

Country Number of Shareholders

United States 115,320 (approx. record) (as of 01/31/2019)

Exchange and Ticker Annual Meeting

NYS : MRK In May

Primary SIC
2834 : Pharmaceutical preparations

Business Summary
Merck & Co. is a global health care
company that delivers
pharmaceutical productshealth
that
consist of therapeutic and
manufactures and markets animal
health products, including

Company Financials

Income Statement
Exchange rate used is that of the
Year End reported date

As Reported Annual Income

Statement
Report Date 12/31/201 12/31/201 12/31/201 12/31/201
Currency USD8 USD7 USD6 USD5
Audit Status Not Not Not Not
Consolidated Qualified
Yes Qualified
Yes Qualified
Yes Qualified
Yes
Scale Thousan Thousan Thousan Thousan
Sales ds
42294000 ds
40122000 ds
39807000 ds
39498000
Cost of sales 13509000 - - -
Selling, general & administrative 10102000 - - -
Materials & production costs - 12775000 13891000 14934000
Marketing & administrative expenses - 9830000 9762000 10313000
Research & development expenses 9752000 10208000 10124000 6704000
Restructuring costs 632000 776000 651000 619000
Interest income 343000 385000 328000 289000
Interest expense 772000 754000 693000 672000
Exchange gains (losses) -145000 11000 -174000 -1277000
Income on investments in equity secur 324000 - - -
Net periodic defined benefit plan (cred 512000 - - -
Equity income from affiliates - 42000 86000 205000
Other income (expense), net 140000 304000 -267000 -72000
Other income (expense), net 402000 -12000 -720000 -1527000
Total costs, expenses & other 33593000 33601000 35148000 34097000
Income (loss) before taxes - domesti 3717000 3483000 518000 2247000
Income (loss) before taxes - foreign 4984000 3038000 4141000 3154000
Income (loss) before taxes (benefit) 8701000 6521000 4659000 5401000
Current income tax provision (benefit) 536000 5585000 1166000 732000
Current income tax provision (benefit) 2281000 1229000 916000 844000
Current income tax provision (benefit) 200000 -90000 157000 130000
Total current provision for income tax 3017000 6724000 2239000 1706000
Deferred income tax provision (benefit -402000 -2958000 -1255000 -552000
Deferred income tax provision (benefit -64000 75000 -225000 -163000
Deferred income tax provision (benefit -43000 262000 -41000 -49000
Total deferred income tax provision (b -509000 -2621000 -1521000 -764000
Taxes on income 2508000 4103000 718000 942000
Net income (loss) 6193000 2418000 3941000 4459000
Less: net income attributable to nonco 27000 -24000 -21000 -17000
Net income (loss) attributable to Merc 6220000 2394000 3920000 4442000
Weighted average shares outstanding 2664000 2730000 2766000 2816000
Weighted average shares outstanding 2679000 2748000 2787000 2841000
Year end shares outstanding ### ### ### ###
Net earnings (loss) per share - basic 2.34 0.88 1.42 1.58
Net earnings (loss) per share - dilute 2.32 0.87 1.41 1.56
Cash dividends paid per common sha 1.99 1.89 1.85 1.81
Total number of employees 69000 69000 68000 68000
Number of common stockholders 115320 121125 128600 135000
Foreign currency translation adjustm -223000 401000 -169000 -208000
Balance Sheet
Exchange rate used is that of the
Year End reported date

As Reported Annual Balance

Sheet
Report Date 12/31/201 12/31/201 12/31/201 12/31/201
Currency USD8 USD7 USD6 USD5
Audit Status Not Not Not Not
Consolidated Qualified
Yes Qualified
Yes Qualified
Yes Qualified
Yes
Scale Thousan Thousan Thousan Thousan
Cash & cash equivalents ds
7965000 ds
6092000 ds
6515000 ds
8524000
Short-term investments 899000 2406000 7826000 4903000
Accounts receivable, gross 7190000 7083000 7213000 6649000
Less: allowance for doubtful account 119000 210000 195000 165000
Accounts receivable, net 7071000 6873000 7018000 6484000
Inventories, net 5440000 5096000 4866000 4700000
Total current assets 25875000 24766000 30614000 29764000
Other current assets 4500000 4299000 4389000 5153000
Investments 6233000 12125000 11416000 13039000
Land 333000 365000 412000 490000
Buildings 11486000 11726000 11439000 12154000
Machinery, equipment & office furnis 14441000 14649000 14053000 14261000
Construction in progress 3355000 2301000 1871000 1525000
Property, plant & equipment, at cost 29615000 29041000 27775000 28430000
Less: allowance for depreciation 16324000 16602000 15749000 15923000
Property, plant & equipment, net 13291000 12439000 12026000 12507000
Goodwill 18253000 18284000 18162000 17723000
Other intangibles, net 11431000 14183000 17305000 22602000
Other assets 7554000 6075000 5854000 6144000
Total assets 82637000 87872000 95377000 ###
Loans payable & current portion of l 5308000 3057000 568000 2585000
Trade accounts payable 3318000 3102000 2807000 2533000
Accrued & other current liabilities 10151000 10427000 10274000 11216000
Income taxes payable 1971000 708000 2239000 1560000
Dividends payable 1458000 1320000 1316000 1309000
Total current liabilities 22206000 18614000 17204000 19203000
Euro-denominated notes 3947000 4126000 3602000 2729000
Floating-rate notes 699000 699000 698000 700000
Notes 14244000 15528000 17989000 18094000
Debentures 691000 691000 832000 834000
Floating-rate borrowing - - 999000 1300000
Other long-term debt 225000 309000 154000 272000
Long-term debt 19806000 21353000 24274000 23929000
Deferred income taxes 1702000 2219000 5077000 6535000
Other noncurrent liabilities 12041000 11117000 8514000 7345000
Common stock 1788000 1788000 1788000 1788000
Other paid-in capital 38808000 39902000 39939000 40222000
Retained earnings 42579000 41350000 44133000 45348000
Derivatives 166000 -108000 338000 404000
Investments -78000 -61000 -3000 41000
Employee benefit plans -3556000 -2787000 -3206000 -2407000
Cumulative translation adjustment -2077000 -1954000 -2355000 -2186000
Accumulated other comprehensive in -5545000 -4910000 -5226000 -4148000
Stockholders' equity subtotal 77630000 78130000 80634000 83210000
Less treasury stock, at cost 50929000 43794000 40546000 38534000
Total Merck & Co., Inc. stockholders' 26701000 34336000 40088000 44676000
Noncontrolling interests 181000 233000 220000 91000
Total equity 26882000 34569000 40308000 44767000

Powered by Clearbit
Pfizer Inc (NYS: PFE)

General Company Information

Principal Office Website
235 East 42nd Street New York, NY www.pfizer.com

Phone Primary NAICS

212 733-2323 325412 : Pharmaceutical Preparation Manufacturing

Auditor Closing Stock Price

KPMG LLP 37.69 (as of 02/04/2020)

Number of Employees Incorporated

92,400 (Approximate Full-Time as of June 1942 , DE, United States

Country Mergent Dividend Achiever

United States No

Exchange and Ticker Number of Shareholders

NYS : PFE 150,398 (record) (as of 02/26/2019)

Primary SIC Annual Meeting

2834 : Pharmaceutical preparations In April

Business Summary
Pfizer is a research-based
biopharmaceutical
includes Co.'s healthcompany.
businessCo.'s
units
(except Consumer Healthcare) as
Lyrica, Lipitor, Norvasc, Viagra and
Celebrex, as well as certain generic

Company Financials

Income Statement
Exchange rate used is that of the
Year End reported date

As Reported Annual Income

Statement
Report Date 12/31/201 12/31/201 12/31/201 12/31/201
Currency USD8 USD7 USD6 USD5
Audit Status Not Not Not Not
Consolidated Qualified
Yes Qualified
Yes Qualified
Yes Qualified
Yes
Scale Thousan Thousan Thousan Thousan
Revenues ds
53647000 ds
52546000 ds
52824000 ds
48851000
Cost of sales 11248000 11240000 12329000 9648000
Selling, informational & administrati 14455000 14784000 14837000 14809000
Research & development expenses 8006000 7657000 7872000 7690000
Amortization of intangible assets 4893000 4758000 4056000 3728000
Restructuring charges & certain acqui 1044000 487000 1724000 1152000
Interest income 333000 391000 470000 471000
Interest expense 1316000 1270000 1186000 1199000
Net interest income (expense) -983000 -879000 -716000 -728000
Foreign currency gain (loss) related - - - -806000
Royalty-related income 495000 499000 905000 922000
Net gains (losses) on asset disposals 71000 343000 171000 232000
Net gains recognized during the perio 586000 - - -
Net realized gains (losses) on sales o -141000 - - -
Income from collaborations, out-lice 488000 - - -
Net periodic benefit costs (credits) ot 288000 - - -
Certain legal matters, net 157000 240000 510000 975000
Certain asset impairments 3115000 395000 1447000 818000
Adjustments to loss on sale of HIS ne - 55000 1712000 -
Loss on sale & impairment on remeas -1000 - - -
Business & legal entity alignment cos 4000 71000 261000 282000
Net losses (gains) on early retirement 3000 999000 - -
Other income (deductions) - net 357000 482000 -85000 -403000
Other income (deductions) - net -2116000 -1315000 -3655000 -2860000
Income (loss) from continuing operati -4403000 -6879000 -8534000 -6809000
Income (loss) from continuing operati16288000 19184000 16886000 15773000
Income (loss) from continuing operati11885000 12305000 8351000 8965000
Current income taxes provision (benefi 668000 14127000 342000 67000
Current income taxes provision (benefi 9000 320000 -52000 -8000
Deferred income taxes provision (benef -1663000 ### -419000 300000
Deferred income taxes provision (benef 16000 -268000 -106000 -36000
Total U.S. tax provision (benefit) -970000 ### -235000 323000
TCJA - current income taxes -3035000 - - -
TCJA - deferred Income taxes 2439000 - - -
Total TCJA tax provision -596000 - - -
Current income taxes provision (benefi2831000 2709000 1532000 1951000
Deferred income taxes provision (benef-558000 28000 -175000 -284000
Total international tax provision 2273000 2737000 1358000 1667000
Provision (benefit) for taxes on inco 706000 -9049000 1123000 1990000
Income from continuing operations 11179000 21353000 7229000 6975000
Income (loss) from discontinued opera 10000 -1000 16000 17000
Gain (loss) on disposal of discontinue - 3000 - -6000
Discontinued operations - net of tax 10000 2000 17000 11000
Net income before allocation to noncon 11188000 21355000 7246000 6986000
Less: net income attributable to nonco -36000 -47000 -31000 -26000
Net income attributable to Pfizer Inc. 11153000 21308000 7215000 6960000
Less: preferred stock dividends, net o 1000 1000 1000 1000
Net income attributable to Pfizer In 11152000 21307000 7214000 6959000
Weighted average shares outstanding 5872000 5970000 6089000 6176000
Weighted average shares outstanding 5977000 6058000 6159000 6257000
Year end shares outstanding 5717000 5979000 6070000 6175000
Earnings (loss) per share from contin 1.9 3.57 1.18 1.13
Net earnings (loss) per share - basic 1.9 3.57 1.18 1.13
Earnings (loss) per share from continu 1.86 3.52 1.17 1.11
Net earnings (loss) per share - dilute 1.87 3.52 1.17 1.11
Cash dividends paid per common sha 1.38 1.28 1.2 1.12
Total number of employees 92400 90200 96500 97900
Number of common stockholders 150398 158190 166694 174703
Foreign currency translation adjustm -821000 1278000 -815000 -3110000

Balance Sheet
Exchange rate used is that of the
Year End reported date

As Reported Annual Balance

Sheet
Report Date 12/31/201 12/31/201 12/31/201 12/31/201
Currency USD8 USD7 USD6 USD5
Audit Status Not Not Not Not
Consolidated Qualified
Yes Qualified
Yes Qualified
Yes Qualified
Yes
Scale Thousan Thousan Thousan Thousan
Cash & cash equivalents ds
1139000 ds
1342000 ds
2595000 ds
3641000
Short-term investments 17694000 18650000 15255000 19649000
Accounts receivable, gross 8566000 8805000 8834000 8560000
Less allowance for doubtful accounts 541000 584000 609000 384000
Trade accounts receivable, net 8025000 8221000 8225000 8176000
Finished goods 2262000 2883000 2293000 2714000
Work in process 4701000 3908000 3696000 3932000
Raw materials & supplies 546000 788000 793000 867000
Inventories 7508000 7578000 6783000 7513000
Current tax assets 3374000 3050000 3041000 2662000
Other current assets 2461000 2289000 2249000 2163000
Assets held for sale 9725000 12000 801000 -
Total current assets 49926000 41141000 38949000 43804000
Long-term investments 2767000 7015000 7116000 15999000
Land 500000 540000 530000 588000
Buildings 9920000 10254000 9810000 9604000
Machinery & equipment 11871000 11902000 11248000 10933000
Furniture, fixtures & other property, 4693000 4661000 4410000 4351000
Construction in progress 2992000 2680000 2127000 1791000
Property, plant & equipment, at cost 29977000 30037000 28125000 27268000
Less: accumulated depreciation 16591000 16172000 14807000 13502000
Property, plant & equipment, less ac 13385000 13865000 13318000 13766000
Identifiable intangible assets, less a 35211000 48741000 52648000 40356000
Goodwill 53411000 55952000 54449000 48242000
Noncurrent deferred tax assets & oth 1924000 1855000 1812000 1794000
Other noncurrent assets 2799000 3227000 3323000 3499000
Total assets ### ### ### ###
Short-term borrowings, including curr 8831000 9953000 10688000 10160000
Trade accounts payable 4674000 4656000 4536000 3620000
Dividends payable 2047000 2029000 1944000 1852000
Income taxes payable 1265000 477000 437000 418000
Accrued compensation & related ite 2397000 2196000 2487000 2359000
Other current liabilities 10753000 11115000 11023000 10990000
Liabilities held for sale 1890000 - - -
Total current liabilities 31858000 30427000 31115000 29399000
Notes 32558000 32783000 - -
Net fair value adjustments related t 479000 872000 - -
Net unamortized discounts, premiums -136000 -125000 - -
Other long-term debt 7000 8000 - -
Long-term debt 32909000 33538000 31398000 28818000
Pension benefit obligations, net 5272000 5926000 6406000 6310000
Postretirement benefit obligations, ne 1338000 1504000 1766000 1809000
Noncurrent deferred tax liabilities 3700000 3900000 30753000 26877000
Other taxes payable 14737000 18697000 4000000 3992000
Other noncurrent liabilities 5850000 6149000 6337000 5257000
Total liabilities 95664000 ### ### ###
Preferred stock 19000 21000 24000 26000
Common stock 467000 464000 461000 459000
Additional paid-in capital 86253000 84278000 82685000 81016000
Treasury stock, shares at cost ### 89425000 84364000 79252000
Retained earnings 89554000 85291000 71774000 71993000
Net unrealized gain (losses) on forei -6075000 -5180000 -6659000 -5863000
Net unrealized gain (losses) on deriva 167000 -30000 348000 421000
Net unrealized gain (losses) on availa -68000 401000 -131000 -227000
Actuarial gains (losses) -6027000 -5262000 -5473000 -4733000
Prior service credits (costs) & other 728000 750000 879000 880000
Accumulated other comprehensive in ### -9321000 ### -9522000
Total Pfizer Inc. shareholders' equity 63407000 71308000 59544000 64720000
Equity attributable to noncontrolling i 351000 348000 296000 278000
Total equity 63758000 71656000 59840000 64998000

Powered by Clearbit
Sanofi (NMS: SNY)

General Company Information

Principal Office Website
54, rue La Boetie Paris, FRA www.sanofi.com

Phone Primary NAICS

(33) 1 53 77 40 00 325412 : Pharmaceutical Preparation Manufacturing

Fax Closing Stock Price

(33) 1 53 77 43 03 48.38 (as of 02/03/2020)

Auditor Incorporated
ERNST & YOUNG et Autres May 1999 , France

Number of Employees Mergent Dividend Achiever

104,226 (Year End Average Staff as No

Country Number of Shareholders

France 24,855 (as of 12/31/2017)

Exchange and Ticker Annual Meeting

NMS : SNY In April

Primary SIC
2834 : Pharmaceutical preparations
Business Summary
Sanofi is a global healthcare
company, focused
franchises; Consumeron patient needs
Healthcare,
which comprises, for all
Vaccines, which comprises, for all
geographical territories, the

Company Financials

Income Statement
Exchange rate used is that of the
Year End reported date

As Reported Annual Income

Statement
Report Date 12/31/201 12/31/201 12/31/201 12/31/201
Currency EUR8 EUR7 EUR6 EUR5
Audit Status Not Not Not Not
Consolidated Qualified
Yes Qualified
Yes Qualified
Yes Qualified
Yes
Scale Millions Millions Millions Millions
Net sales 34463 35055 33821 34542
Other revenues 1214 1149 887 319
Cost of sales -11435 -11611 -10702 -10919
Gross profit 24242 24593 24006 23942
Research & development expenses -5894 -5472 -5172 -5082
Selling & general expenses -9859 -10058 -9486 -9382
Other operating income 484 237 355 254
Other operating expenses -548 -233 -482 -462
Amortization of intangible assets -2170 -1866 -1692 -2137
Impairment of intangible assets -718 -293 -192 -767
Fair value remeasurement of contingent 117 -159 -135 53
Restructuring costs & similar items -1480 -731 -879 -795
Other gains & losses, & litigation 502 -215 211 -
Operating income 4676 5803 6534 5624
Cost of debt -396 -277 -274 -331
Non-operating foreign exchange gains - -21 -21 -
Unwinding of discounting of provision -24 -33 -33 -44
Net interest cost related to employee -75 -92 -114 -114
Impairment losses on financial assets, - -7 -487 -50
Other items - - -19 -
Financial expenses -435 -420 -924 -559
Interest income 123 56 56 57
Non-operating foreign exchange gains 6 - - -
Gains/(losses) on disposals of financi 63 96 36 46
Other items 32 5 - 55
Financial income 164 147 68 178
Income before tax & investments acco 4405 5530 5678 5243
Income tax expense -481 -1722 -1326 -709
Share of profit/(loss) from investmen 499 104 134 -22
Net income excluding the held-for-e 4423 3912 4486 4512
Net income/(loss) of the held-for-ex -13 4643 314 -124
Net income 4410 8555 4800 4388
Net income attributable to non-control 104 121 91 101
Net income attributable to Group equi 4306 8434 4709 4287
Weighted average ordinary shares out 1247.1 1256.9 1286.6 1306.2
Weighted average ordinary shares out 1255.2 1266.8 1296 1320.7
Year end shares outstanding 1245.454 1253.846 1271.938 1301.74
Basic earnings per share 3.45 6.71 3.66 3.28
Diluted earnings per share 3.43 6.66 3.63 3.25
Dividends per share 3.07 - 2.96 -
Number of common stockholders - 24855 24794 -
Total number of employees 104226 106566 106859 115631

Balance Sheet
Exchange rate used is that of the
Year End reported date

As Reported Annual Balance

Sheet
Report Date 12/31/201 12/31/201 12/31/201 12/31/201
Currency EUR8 EUR7 EUR6 EUR5
Audit Status Not Not Not Not
Consolidated Qualified
Yes Qualified
Yes Qualified
Yes Qualified
Yes
Scale Millions Millions Millions Millions
Property, plant & equipment, gross 22697 21978 21877 21109
Depreciation & impairment - property -13046 -12399 -11858 -11166
Property, plant & equipment 9651 9579 10019 9943
Goodwill 44235 40264 40287 39557
Other intangible assets 21889 13080 10879 12026
Investments accounted for using the 3402 2863 2890 2676
Available-for-sale financial assets - 2182 - -
Financial assets recognized under the - 336 - -
Pre-funded pension obligations - 53 - -
Long-term loans & advances & other - 730 - -
Derivative financial instruments - 63 - -
Other non-current assets 2971 3364 2820 2725
Deferred tax assets 4613 4290 4669 4714
Total non-current assets 86761 73440 71564 71641
Inventories 7477 6816 6892 6516
Accounts receivable, gross 7430 7405 7506 7553
Impairment - accounts receivable -170 -189 -195 -167
Accounts receivable 7260 7216 7311 7386
Taxes recoverable 1458 832 1034 1006
Other receivables 627 627 705 461
Prepaid expenses 469 336 333 300
Interest rate derivatives measured at 30 - 3 -
Currency derivatives measured at fair 134 133 105 -
Other current financial assets 199 77 31 -
Other current assets 2917 2005 2211 1767
Current financial assets - - - 111
Cash & cash equivalents 6925 10315 10273 9148
Totla current assets 24579 26352 26687 24928
Assets held for sale or exchange 68 34 6421 5752
Total assets 111408 99826 104672 102321
Share capital 2495 2508 2584 2611
Additional paid-in capital & retained 53106 52882 51477 52010
Treasury shares -153 -14 -1503 -298
Stock options & other share-based p 3596 3298 3032 2814
Other comprehensive income (loss) -168 -585 1964 912
Equity attributable to equity holders o 58876 58089 57554 58049
Equity attributable to non-controlling 159 169 170 161
Total equity 59035 58258 57724 58210
Long-term debt 22007 14326 16815 13118
Non-current liabilities related to bus 963 1026 1378 1121
Non-current provisions & other non curr 8613 9154 8834 9169
Deferred tax liabilities 3414 1605 2292 2895
Total non-current liabilities 34997 26111 29319 26303
Accounts payable 5041 4633 4297 3817
Current liabilities related to business 341 343 198 130
Current provisions & other current liabi 9361 9206 10175 9442
Short-term debt & current portion of 2633 1275 1764 3436
Total current liabilities 17376 15457 16434 16825
Liabilities related to assets held for - - 1195 983
Total equity & liabilities 111408 99826 104672 102321

Powered by Clearbit
Novartis AG Basel (NYS: NVS)

General Company Information

Principal Office Website
Lichtstrasse 35 Basel, CHE www.novartis.com
Phone Primary NAICS
(41) 61 324 1111 325412 : Pharmaceutical Preparation Manufacturing

Fax Closing Stock Price

(41) 61 324 7826 95.1 (as of 02/04/2020)

Auditor Incorporated
PricewaterhouseCoopers AG July 1895 , Switzerland

Number of Employees Mergent Dividend Achiever

125,161 (Year End Average Staff as No

Country Number of Shareholders

Switzerland 163,000 (approx.) (as of 12/31/2018)

Exchange and Ticker Annual Meeting

NYS : NVS In February

Primary SIC
2834 : Pharmaceutical preparations

Business Summary
Novartis is a multinational group
focusing
operatingon the research,
divisions: Innovative
Medicines Division, which
pharmaceutical active substances;
and Alcon Division, which

Company Financials

Income Statement
Exchange rate used is that of the
Year End reported date

As Reported Annual Income

Statement
Report Date 12/31/201 12/31/201 12/31/201 12/31/201
Currency USD8 USD7 USD6 USD5
Audit Status Not Not Not Not
Consolidated Qualified
Yes Qualified
Yes Qualified
Yes Qualified
Yes
Scale Millions Millions Millions Millions
Net sales to third parties 51900 49109 48518 49414
Sales to discontinuing segments - - - 26
Total net sales from continuing opera - 49109 48518 49440
Other revenues 1266 1026 918 947
Cost of goods sold -18407 -17175 -17520 -17404
Gross profit 34759 32960 31916 32983
Selling, general & administrative -16471 - - -
Marketing & sales - -12861 -11998 -11772
Research & development -9074 -8972 -9039 -8935
General & administration - -2136 -2194 -2475
Other income 1690 1969 1927 2049
Other expense -2735 -2331 -2344 -2873
Operating income 8169 8629 8268 8977
Income from associated companies 6438 1108 703 266
Interest expense -957 -777 -707 -655
Interest income 294 110 43 33
Dividend income 1 1 1 1
Net capital (losses)/gains on available - -1 -1 -8
Income on forward contracts & option - - - 1
Impairment of commodities & available -2 12 7 -132
Other financial expense -33 -25 -20 -23
Monetary loss from hyperinflation ac -10 - - -72
Currency result, net -65 -58 -477 -254
Other financial income & expense 185 39 -447 -454
Income before taxes 13835 8999 7817 8134
Taxes -1221 -1296 -1119 -1106
Net income from continuing operatio - 7703 6698 7028
Net income from discontinuing operat - - - 10766
Net income 12614 7703 6698 17794
Net income attributable to shareholde 12611 7703 6712 17783
Net income attributable to non-control 3 0 -14 11
Weighted average ordinary shares ou 2319 2346 2378 2403
Weighted average ordinary shares out 2344 2371 2400 2438
Year end shares outstanding 2311.2 2317.5 2374.059 2373.895
Basic earnings per share - continuing - 3.28 2.82 2.92
Basic earnings (loss) per share - dis - - - 4.48
Basic earnings per share 5.44 3.28 2.82 7.4
Diluted earnings per share - continui - 3.25 2.8 2.88
Diluted earnings (loss) per share - d - - - 4.41
Diluted earnings per share 5.38 3.25 2.8 7.29
Dividends per share 2.8 2.75 2.7 2.6
Total number of employees 125161 121597 118393 118700
Number of stockholders 163000 167000 170522 160879

Balance Sheet
Exchange rate used is that of the
Year End reported date

As Reported Annual Balance

Sheet
Report Date 12/31/201 12/31/201 12/31/201 12/31/201
Currency USD8 USD7 USD6 USD5
Audit Status Not Not Not Not
Consolidated Qualified
Yes Qualified
Yes Qualified
Yes Qualified
Yes
Scale Millions Millions Millions Millions
Property, plant & equipment, gross 34028 34010 31296 31448
Accumulated depreciation - property, -18332 -17546 -15655 -15466
Property, plant & equipment, net 15696 16464 15641 15982
Goodwill, net 35294 31750 30980 31174
Intangible assets other than goodwill 38719 29997 31340 34217
Investment in associated companies 8352 15370 14304 15314
Deferred tax assets 8699 8229 10034 8957
Financial assets 2345 2243 2196 2466
Other non-current non-financial asset - 818 698 601
Other non-current assets 895 - - -
Total non-current assets 110000 104871 105193 108711
Inventories 6956 6867 6255 6226
Trade receivables, gross 8853 8790 8364 8322
Provision for doubtful trade receivabl -126 -190 -162 -142
Trade receivables 8727 8600 8202 8180
Income tax receivables 248 202 - -
Marketable securities, commodities, t 2693 625 770 773
Cash & cash equivalents 13271 8860 7007 4674
Other current assets 2861 3054 2697 2992
Total current assets without disposal 34756 - - -
Assets held for sale related to disco 807 - - -
Total current assets 35563 28208 24931 22845
Total assets 145563 133079 130124 131556
Share capital 944 969 972 991
Treasury shares -69 -100 -76 -101
Reserves 77739 73299 73936 76156
Issued share capital & reserves attri 78614 74168 74832 77046
Non-controlling interests 78 59 59 76
Total equity 78692 74227 74891 77122
Straight bonds 25283 22957 - -
Liabilities to banks & other financial i 285 539 - -
Finance lease obligations 92 87 - -
Total, including current portion of non 25660 23583 - -
Less current portion of non-current fi -3190 -359 - -
Financial debts 22470 23224 17897 16327
Deferred tax liabilities 7475 5168 6657 6355
Provisions & other non-current liabilit 7319 7057 8470 8044
Total non-current liabilities 37264 35449 33024 30726
Trade payables 5556 5169 4873 5668
Financial debts & derivative financial 9678 5308 5905 5604
Current income tax liabilities 2038 1723 1603 1717
Provisions & other current liabilities 12284 11203 9828 10719
Total current liabilities without dispos 29556 - - -
Liabilities of disposal group held for s 51 - - -
Total current liabilities 29607 23403 22209 23708
Total liabilities 66871 58852 55233 54434
Total equity & liabilities 145563 133079 130124 131556